Articles tagged with Neuropathic Pain
Researchers at Okayama University discovered EPA's molecular target, which blocks purinergic chemical transmission and reduces pain perception. The study suggests EPA can be used as a therapeutic strategy for managing chronic pain with fewer side effects.
A multidisciplinary team at UVA Health will use deep brain stimulation to treat refractory neuropathic pain, aiming to modulate pain signals from the insula. The study may shed light on the fundamental nature of pain and identify biological indicators for effective treatment.
A systematic review of cannabis-related products found short-term benefits for neuropathic pain, particularly with dronabinol and nabilone. However, the evidence is limited, with many products not well-studied, and patients should consult their primary care physician before using cannabis-based treatments.
Research found that stimulating a specific brain circuit relieves pain and reduces defensive behaviors in rats, indicating potential physical and psychological relief. The pathway also increases reward and feeding behavior, suggesting improved emotional state.
Researchers have found blood proteins that cause migraine, including DKK1 and PDGFB, which inhibit Wnt signalling pathways. Lower levels of antioxidant proteins FARS2, GSTA4, and CHIC2 also contribute to inflammation linked to migraine. Therapies targeting increased DKK1 levels may represent novel tools for treatment.
A gene therapy approach has effectively reduced neuropathic pain in mice with spinal cord or peripheral nerve injuries without detectable side effects. The treatment, which targets impaired neurons, resulted in long-lasting benefits persisting for at least 2.5 months.
A new wireless implant has the potential to treat neuropathic pain resistant to medical therapy, offering a minimally invasive alternative to surgery. The device uses bioelectronic therapy to stimulate peripheral nerves from within blood vessels, providing precise placement and predictable outcomes.
A new synthetic substance, PECS-101, has been shown to prevent neuropathic pain caused by chemotherapy while improving cancer treatment outcomes. The study, conducted in mice, found that PECS-101 had no adverse effects and did not cause dependence.
Adults with spinal cord injuries have a near-80% increased risk of developing psychological conditions compared to those without the injury. Chronic pain is equally negatively impacting mental health, associated with post-traumatic stress disorder and other mental health conditions in most cases.
The UArizona Health Sciences Center is developing a Center of Excellence for Addiction Studies to advance addiction research and develop therapies for the opioid epidemic. The center will facilitate national collaborations, employ cutting-edge genetic techniques, and provide advanced methods for measuring neurotransmitters.
Researchers developed a compound that regulates a biological channel linked to pain, reducing the sensation of pain in rodents. The compound, dubbed 194, successfully targets sodium ion channels and promotes pain relief by activating the body's endogenous opioid system.
Researchers at University of California San Diego School of Medicine identified the anterior insula's role in predicting and emotionally processing pain in HIV-DSP patients. The study suggests that reduced anterior insula activity or increased cingulate activity may improve pain outcomes for these patients.
Researchers at Duke University and UC Irvine identify Kenpaullone, a cancer drug, as an effective analgesic for chronic and challenging-to-treat pain. The compound enhances Kcc2 gene expression, which resets maladaptive genetic switches in neurons, leading to pain signal silencing.
Scientists at Temple University will explore the therapeutic potential of KLS-13019, a CBD analog that shows promise as an opioid alternative. The Phase 2 SBIR grant aims to test the compound's effects on rat models of neuropathic pain, shedding light on its safety and efficacy.
Researchers at the University of Alabama at Birmingham discovered a small molecule that potently attenuates neuroinflammation in brain and glial cells. This finding presents a promising new approach to treat neurological diseases driven by neuroinflammation, such as stroke, spinal cord injury, and neuropathic pain.
Researchers at Monash University have discovered a new mode of targeting the adenosine A1 receptor protein, which could lead to the development of non-opioid painkillers to treat chronic neuropathic pain. The study provides an opportunity for researchers to develop safer and more effective drugs.
A recent study found that patients with unilateral nerve injuries often experience sensory abnormalities on the opposite side of their body, regardless of whether they have pain or not. This phenomenon, known as contralateral sensory abnormalities, suggests a common underlying mechanism for both painful and painless neuropathies.
Scientists have identified a new cell type, MRC1+ macrophages, involved in chronic pain and inflammation. Stimulating the expression of an anti-inflammatory protein CD163 can reduce neuroinflammation and relieve neuropathic pain.
A uOttawa study finds that mindfulness can significantly impact the brain of women suffering from neuropathic pain related to breast cancer treatment. The research shows major reductions in brain activity and a significant improvement in brain health as well as pain perception.
The new issue of NeuroRehabilitation focuses on the challenges of classifying, assessing, and treating neurogenic pain disorders. Experts describe the latest advancements in neurogenic classification and pain management, including new treatment options for peripheral neuropathic pain, complex regional pain syndrome, and craniofacial ne...
Researchers at UNM demonstrated that legal cannabis hemp oil reduced mechanical pain sensitivity by 10-fold in mice with chronic post-operative neuropathic pain. The study's findings suggest that hemp oil can be an effective treatment for chronic pain, offering a natural and relatively safe alternative to conventional drugs.
A study published in Journal of Neuroscience reveals that FLRT3 protein, involved in neuron development and cell adhesion, is also critical for pain sensitization. High levels of FLRT3 protein were found in the dorsal horn following nerve injury, leading to touch sensitivity and mechanical allodynia.
The Kessler Foundation will conduct a pilot study using functional MRI to develop new strategies for managing neuropathic pain in individuals with spinal cord injuries. The study aims to train participants to use neurofeedback to modulate their brain activity and reduce pain sensations.
Researchers have discovered genetic evidence of chronic pain in Drosophila fruit flies, which may lead to new treatments targeting the underlying cause. The study found that an injury can lead to long-lasting hypersensitivity to normally non-painful stimuli, similar to human patients' experiences with neuropathic pain.
A computational model simulates how pain is transmitted from a nerve to the spinal cord's dorsal horn, reproducing experimental results on pain sensitivity. The model suggests a potential mechanism for neuropathic pain's flipped sensitivity rhythm: a change from inhibition to excitation in synaptic connections between nerve cells.
Researchers at SLU discovered a molecular pathway required for neuropathic pain and found blocking this signal can limit or stop pain. A new class of non-narcotic pain-killing therapies is being developed.
Processed aconite root relieves neuropathic pain in murine models, with neoline emerging as the active compound. Neoline is stable and shows promise for pain alleviation.
A new study in mice reveals that sociable personalities attenuate neuropathic pain, while anxiety intensifies it. High expression of genes IL6 and PDYN in the amygdala correlates with increased pain sensitivity.
A new study published in Cell suggests that targeting immune cells called natural killer cells may help clear out damaged axons and promote healthy regrowth, potentially decreasing chronic neuropathic pain. The findings could lead to a greater understanding of the mechanisms behind neuropathic pain and improve treatment options.
Researchers at Scripps Research have identified the molecule PIEZO2 as responsible for tactile allodynia, a condition characterized by pain from gentle touch. The study provides validation that targeting PIEZO2 could be beneficial in treating this common form of chronic pain.
Researchers have isolated a volume control in the brain for pain and identified a small group of neurons in the cortex that can amplify touch sensation. Silencing these neurons may help break a feedback loop that introduces and exaggerates the pain response to normally non-painful touch.
Researchers have found a novel therapeutic that interrupts signaling cascades in the body required for multiple forms of neuropathic pain. The treatment targets the nNOS-NOS1AP protein-protein interactions, reducing neuropathic pain in rodents and disrupting nociceptive signaling.
Scientists at EMBL Rome developed a light-sensitive chemical that selectively binds to nerve cells causing neuropathic pain, leading to pain relief. The method avoids targeting single molecules and shows promise for managing chronic pain in humans.
Researchers uncover mechanism behind neuropathic pain and develop innovative treatment blocking FLT3 molecule. The treatment shows immediate and long-lasting therapeutic effects in animal subjects, reducing hyperalgesia and allodynia.
A recent study has identified distinct cellular origins for different symptoms of neuropathic pain, paving the way for targeted treatments. The research found that cold allodynia is exclusively neuronal in nature, while tactile allodynia involves complex interactions between the immune system and nervous system.
Researchers discovered a previously unknown cellular communication method between neurons and immune cells in neuropathic pain. Blocking this method could prevent neuropathic pain without side effects.
Researchers have discovered a potent pain reliever, UKH-1114, that targets the sigma 2 receptor to alleviate neuropathic pain. The compound is as effective as gabapentin but works at a lower dose and longer duration, offering a potential alternative to opioids.
Researchers discovered a novel therapeutic target called LPCAT2 that could effectively treat neuropathic pain. The study also identified a platelet alleviating factor (PAF) pain loop that affects neuropathic pain, suggesting potential benefits from PAF-receptor antagonists.
Researchers discovered that microglia brain immune cells play a major role in the initiation and maintenance of neuropathic pain. Targeting these cells within a few days after nerve injury can greatly reduce chronic pain in animals. This breakthrough could lead to more effective painkillers with fewer side effects.
Neuropathic pain is a common complication of spinal cord injuries, affecting every person differently. The new guidelines recommend screening and diagnosis, treatment models, and care approaches to manage pain and ensure patients can fully benefit from rehabilitation.
A recent analysis found that approximately 43% of the UK population, around 28 million adults, suffer from chronic pain. The prevalence is expected to rise as the population ages, with older individuals being more likely to experience long-term pain. Women are also more likely to be affected by chronic pain than men.
Recent discoveries shed light on the mechanism underlying neuropathic pain, revealing a reduced inhibition of pain signal transmission due to dysregulation of chloride levels. This leads to hyperexcitability in neurons, causing touch-evoked pain.
A study by researchers at the University of Texas M. D. Anderson Cancer Center found that gene therapy may be able to reverse cancer-related nerve pain. The treatment, which involves transferring a gene called KCC2 into the spinal canal, restored chloride levels and eliminated pain hypersensitivity in rats.
A study published in The Journal of Clinical Investigation identified a key role for S1 astrocytes in sustaining mechanical allodynia. Researchers found that specific signaling pathways activated in the brain contribute to neuropathic pain, suggesting new therapeutic targets.
A University of Alberta study found that patients without opioid prescriptions experienced improved physical functioning and reduced disability compared to those who received opioid treatment for neuropathic pain. The research suggests a graded approach to physical activity may help improve function despite chronic pain.
A consensus approach to assessing neuropathic pain phenotypes has been developed by an international panel of experts, aiming to improve consistency and transparency in studies. The new criteria identify possible cases of neuropathic pain, emphasizing the need for additional assessments to confirm diagnosis.
A study at Mount Sinai Hospital found that antidepressants regulate chronic pain and depression through actions in the nucleus accumbens, a key brain reward center. The research discovered a gene (RGS9) controlling molecular adaptations for recovery from pain and depression.
A research group at Hiroshima University found that downregulated spinal astrocyte connexin43 expression leads to sustained neuropathic pain following peripheral nerve injury. Restoring Cx43 function via adenovirus vector may reverse mechanical hypersensitivity and modulate glutamatergic neurotransmission.
Scientists at UC Davis have identified endoplasmic reticulum stress as the significant driver of neuropathic pain. The discovery opens new avenues for treating chronic pain from various conditions, such as diabetes and multiple sclerosis.
A new compound named 8-Gly carb has been discovered by UC Davis researchers to potentiate the inhibition of nitrous oxide production, implicated in chronic pain syndromes. The findings offer an important avenue for developing drugs to prevent neuropathic pain without interfering with recovery.
A new study by University of Bristol researchers found that percutaneous electrical nerve stimulation (PENS) therapy reduces signs of headshaking in horses. The treatment, also used to manage neuropathic pain in people, showed promising medium-term remission results for five out of seven affected horses.
A study published in Neural Regeneration Research found that electroacupuncture can significantly attenuate chronic neuropathic pain in rats with brachial plexus injuries. The treatment was shown to increase β-endorphin expression, which may contribute to its analgesic effects.
The study implanted 125I seeds into rat dorsal root ganglia to provide relief for neuropathic pain. Results showed elevated mechanical pain threshold without influencing motor functions, suggesting neuronal microdamage as the primary mechanism. The findings have potential implications for developing novel pain management therapies.
Researchers have discovered how cone snail venom Vc1.1 works to reduce neuropathic pain by targeting specific calcium channels in neurons. This breakthrough could lead to the development of synthetic versions of Vc1.1 to treat certain types of chronic pain.
A new drug treatment has been found to be effective against chronic pain caused by nerve damage, including post-herpetic neuralgia. Fifty-eight per cent of participants taking the drug found it effective, reducing pain by at least 30 per cent.
Researchers found acupuncture activates ephrin-B/EphB signaling, potentially improving pain and repairing injured nerves. The study provides insight into the mechanisms underlying acupuncture's effects on neuropathic injury and pain.
Neuropathic pain is a daily reality for millions of Americans, but researchers have found a way to protect GABA neurons from oxidative stress, which may help alleviate the condition. By using an antioxidant compound, scientists were able to lower pain behavior and preserve GABA neuron populations.
A Duke University study found that a compound called neuroprotectin D1 can relieve neuropathic pain caused by nerve injuries. The derivative of DHA, a main ingredient of fish oil supplements, inhibits the production of cytokines and chemokines, protecting nerve cells from further damage.
Researchers at UTMB are using gene therapy to target the serotonin 2C receptor in the amygdala to prevent abnormal pain generation and treatment resistance. They aim to develop a permanent solution to neuropathic pain, which affects millions of Americans.
A key protein in Schwann cells is essential for normal interactions between nerve cells and Schwann cells, regulating the steps that lead to nerve regeneration. Deficiency of this protein may lead to chronic neuropathic pain, motivating the development of a small molecule drug to mimic its function.